Last week, WHO announced prequalification of the first conjugate vaccine to prevent typhoid (Typbar TCV, manufactured by Bharat Biotech, India) after the publication of randomised controlled trials, including that by Celina Jin and colleagues in The Lancet on Sept 28, 2017. WHO has decided that Typbar TCV was successfully assessed for quality, safety, and efficacy, and it is now approved for distribution by UN agencies. Already in use in India and Nepal in babies older than 6 months, the vaccine is to be licensed for use in infants younger than 2 years.

中文翻译：

---

一种新型的伤寒控制疫苗

上周，在随机对照试验（包括Celina Jin及其同事于2017年9月28日在《柳叶刀》上）发表后，世卫组织宣布对首个预防伤寒的结合疫苗（Typbar TCV，印度巴拉特生物技术公司生产）进行资格预审。我们已经确定Typbar TCV已成功评估了质量，安全性和功效，现已获得联合国机构的批准。该疫苗已在印度和尼泊尔的6个月以上的婴儿中使用，已获许可在2岁以下的婴儿中使用。